Compound ID | 2879
Class: Beta-lactam + beta-lactamase inhibitor
| Spectrum of activity: | Gram-negative |
| Details of activity: | Active against Enterobacteriaceae; nacubactam (OP0595) inhibits serine beta-lactamases and penicillin-binding protein 2 in Enterobacteriaceae additionally enhances beta-lactam agents targeting PBPs other than PBP2 in Enterobacteriaceae |
| Combined with other compounds: | Yes |
| Description: | Synthetic compound; combination of beta-lactam and diazabicyclooctane beta-lactamase inhibitor |
| Institute where first reported: | Meiji Seika Pharma and Fedora Pharmaceuticals; Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, Public Health England, London, UK |
| Year first mentioned: | 2015 |
| Highest developmental phase: | Phase 3 (NCT05887908) |
| Development status: | Active as of 2024 |
| Chemical structure(s): | |||||||||||||
|
|
||||||||||||
|
|
||||||||||||
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/5742832 |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/73386748 |
| Citation: | https://academic.oup.com/jac/article/70/11/3032/2364032?login=true |